Horizon Pharma plc Names George Hampton Executive Vice President, Global Orphan Business Unit and International Operations

Go back to Horizon Pharma plc Names George Hampton Executive Vice President, Global Orphan Business Unit and International Operations

Brean Capital Remains Bullish on Horizon Pharma (HZNP) Following 2Q Beat

August 10, 2015 6:51 AM EDT

Brean Capital reiterated a Buy rating and $40 price target on Horizon Pharma (NASDAQ: HZNP) following the release of its 2Q15 earnings results. revenue was $172.8 million beating consensus estimates of $156.4. Non-GAAP EPS was $0.39 beating consensus' $0.32.

Analyst Difei Yang commented, "Given the pre-announcement of... More